Sana has a lot of money and little to share
In early 2019, Sana Biotechnology emerged with a light-on-detail plan to corner the market on cell and gene therapies. Today we know, officially, the company has raised $700 million.
As STAT’s Kate Sheridan and Adam Feuerstein report, Sana’s Series A round is by far the largest in recent biotech memory. The company didn’t disclose financial details, but the fundraise undoubtedly makes Sana a unicorn — a private firm with a valuation exceeding $1 billion.
As for what that money buys, Sana CEO Steve Harr taciturn. The company has more than 200 employees tasked with developing cell and gene therapies for a host of conditions including cancer, neurological disease, and genetic disorders. Sana even has an in-house answer to Google’s famed moonshot factory, scientists “pushing those things that we would love to be able to do but we just can’t quite do yet,” Harr said.
Read more.
As STAT’s Kate Sheridan and Adam Feuerstein report, Sana’s Series A round is by far the largest in recent biotech memory. The company didn’t disclose financial details, but the fundraise undoubtedly makes Sana a unicorn — a private firm with a valuation exceeding $1 billion.
As for what that money buys, Sana CEO Steve Harr taciturn. The company has more than 200 employees tasked with developing cell and gene therapies for a host of conditions including cancer, neurological disease, and genetic disorders. Sana even has an in-house answer to Google’s famed moonshot factory, scientists “pushing those things that we would love to be able to do but we just can’t quite do yet,” Harr said.
Read more.
No hay comentarios:
Publicar un comentario